Spruce Biosciences, Inc.
SPRBD
$8.20
-$0.30-3.53%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 697.00K | 602.00K | 1.61M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 697.00K | 602.00K | 1.61M |
| Cost of Revenue | -6.00K | 10.84M | 21.46M | 6.55M | 7.41M |
| Gross Profit | 6.00K | -10.84M | -20.76M | -5.95M | -5.80M |
| SG&A Expenses | 3.12M | 3.66M | 3.31M | 3.46M | 3.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.69M | 14.49M | 24.77M | 10.01M | 11.65M |
| Operating Income | -2.69M | -14.49M | -24.07M | -9.41M | -10.04M |
| Income Before Tax | -2.07M | -14.04M | -23.56M | -8.67M | -9.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.07M | -14.04M | -23.56M | -8.67M | -9.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.07M | -14.04M | -23.56M | -8.67M | -9.18M |
| EBIT | -2.69M | -14.49M | -24.07M | -9.41M | -10.04M |
| EBITDA | -2.69M | -14.49M | -24.07M | -9.40M | -10.02M |
| EPS Basic | -3.50 | -23.96 | -42.58 | -15.75 | -16.73 |
| Normalized Basic EPS | -2.19 | -14.98 | -26.61 | -9.84 | -10.46 |
| EPS Diluted | -3.50 | -23.96 | -42.58 | -15.75 | -16.73 |
| Normalized Diluted EPS | -2.19 | -14.98 | -26.61 | -9.84 | -10.46 |
| Average Basic Shares Outstanding | 591.10K | 585.90K | 553.30K | 550.70K | 548.80K |
| Average Diluted Shares Outstanding | 591.10K | 585.90K | 553.30K | 550.70K | 548.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |